Pfizer’s top two bidders may have both walked away from a consumer health deal last week, but that doesn’t mean the pharma giant doesn’t still have options.
On the contrary, it’s got one path left to unloading the unit, and it’s one the company’s plenty familiar with: a spinoff.
As Bloomberg notes, a spinoff would not only spare Pfizer the taxes it would have had to pay on sale proceeds, but spinning off the unit could take some debt off Pfizer’s hands, too. And the company, which executed a successful spinoff of animal health unit Zoetis in 2013, knows what it’s doing in that department.
Of course, Pfizer, which had reportedly been looking for $20 billion or more before GlaxoSmithKline and Reckitt Benckiser backed out of talks, could still decide to keep the division until a better buyer comes calling. The business is still growing—at a rate of between 2% to 4% per year—and the portfolio accounts for a significant chunk of its dividend.
Plus, the company has made clear that it doesn’t have an immediate need for cash. “I suppose if no one is prepared to pay their asking price, then why sell it?” Daniel Mahony, a partner with Polar Capital in London, said.
But with online retailers putting the squeeze on drugstores, waiting around isn’t necessarily such a great idea, some industry watchers contend.
“The world has changed,” UBS Group analyst Michael Leuchten told Bloomberg. “That means these businesses or assets probably won’t be able to fetch the multiples they have in the past.”
By Carly Helfand
Source: Fierce Pharma
Thermo Fisher Scientific Inc. (Waltham, Mass.) announced that the company has entered into a definitive agreement with Solventum to acquire Solventum’s Purification & Filtration business for approximately $4.1 billion in cash.
According to Lilly, three of the future US sites will focus on manufacturing active pharmaceutical ingredients (API), reshoring critical capabilities of small molecule chemical synthesis and further strengthening its supply chain. The fourth location will extend the company’s global parenteral manufacturing network for future injectable therapies.
Dassault Systèmes announced that a beta test is underway to evaluate a new generation of the Living Heart model that can be customized for individual patients or patient populations. The test aims to deliver a level of configuration and automation that makes the model an improved resource for simplifying medical device research and development.
